Nycomed is a pharmaceutical company dedicated to improving the quality of patients’ lives.

The company provides hospital products worldwide and general practitioner and pharmacy medicines in selected markets.

New products are sourced through our own research and through licensing agreements with research companies. Here Nycomed provides late-stage clinical development, registration and marketing.

Headquartered in Zürich, Switzerland, the company employs about 12,000 people, operating extensively throughout Europe and in fast-growing markets in Latin America, Russia/CIS and Asia-Pacific.

Nycomed is privately owned and had estimated annual sales of approximately € 3.4 billion in 2006.

Nycomed operates in the following markets: 

• Europe: Austria, Belgium, Bosnia-Herzegovina, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Serbia/Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland and United Kingdom.
• Americas: USA, Canada, Mexico, Argentina and Brazil.
• Russia/CIS: Russia and the Commonwealth of Independent States.
• Asia Pacific: P.R. China, Hong Kong, India, Japan, Korea, Malaysia, Philippines, Australia and South Africa.

Nycomed has production facilities in Austria, Belgium, Brazil, Denmark, Estonia, Finland, Germany, India, Ireland, Mexico, Norway, Poland and the USA.

Nycomed’s R&D facilities are led out of Konstanz, Germany, with additional sites in Denmark and India.